<DOC>
	<DOCNO>NCT02300558</DOCNO>
	<brief_summary>This study evaluate effect eleclazine shorten correct QT interval ( QTc ) , safety , tolerability adult type 3 long QT syndrome ( LQT3 ) . During single-blind treatment period ( 24 week ) , participant receive eleclazine and/or eleclazine placebo . Following single-blind treatment period , participant permanently discontinue study drug eligible , discretion investigator , continue receive eleclazine open-label extension phase .</brief_summary>
	<brief_title>Effect Eleclazine Shortening QT Interval , Safety , Tolerability Adults With Long QT Syndrome Type 3</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Long QT Syndrome</mesh_term>
	<criteria>Key Individuals establish diagnosis LQT3 ( genotype testing ) Mean ( triplicate ) QTc interval ≥ 480 msec ( ≥ 460 msec , individual currently take ranolazine Class I antiarrhythmic drug mexiletine ) 3 time point , determine standard 12lead ECG , screen Key Known mutation associate type 1 long QT syndrome ( LQT1 ) type 2 long QT syndrome ( LQT2 ) Known suspect history seizure epilepsy History heart failure define New York Heart Association ( NYHA ) Class IV and/or know left ventricular ejection fraction ( EF ) ≤ 45 % Body mass index ( BMI ) ≥ 40 kg/m^2 screen Severe renal impairment screening ( define estimate glomerular filtration rate ( eGFR ) &lt; 30 mL/min/1.73m^2 , use 4 Variable Modification Diet Renal Disease ( MDRD ) equation , determine study center ) Abnormal liver function test screen , define alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2 x upper limit normal ( ULN ) , total bilirubin &gt; 1.5 x ULN An aborted cardiac arrest ( ACA ) , implantable cardioverterdefibrillator ( ICD ) implantation , syncopal episode , appropriate ICD therapy within 3 month prior screen Any condition circumstance opinion investigator would preclude compliance study protocol Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>LQT3</keyword>
	<keyword>long QT syndrome</keyword>
	<keyword>congenital long QT</keyword>
	<keyword>sudden cardiac death</keyword>
</DOC>